Article Cited by others

REVIEW

Treatment sequencing in metastatic castrate-resistant prostate cancer

Sartor Oliver, Gillessen Silke

Year : 2014| Volume: 16| Issue : 3 | Page no: 426-431

   This article has been cited by
 
1 Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer
Robert B. Den,Daniel George,Christopher Pieczonka,Megan McNamara
American Journal of Clinical Oncology. 2019; 42(4): 399
[Pubmed]  [Google Scholar] [DOI]
2 Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
Simon Linder,Henk G van der Poel,Andries M Bergman,Wilbert Zwart,Stefan Prekovic
Endocrine-Related Cancer. 2019; : R31
[Pubmed]  [Google Scholar] [DOI]
3 ErbB-2 signaling in advanced prostate cancer progression and potential therapy
Dannah R Miller,Matthew A Ingersoll,Ming-Fong Lin
Endocrine-Related Cancer. 2019; 26(4): R195
[Pubmed]  [Google Scholar] [DOI]
4 The Androgen Receptor Splice Variant AR-V7 as a Biomarker of Resistance to Androgen-axis Targeted Therapies in Advanced Prostate Cancer
Tian Zhang,Lawrence I. Karsh,Michael J. Nissenblatt,Steven E. Canfield
Clinical Genitourinary Cancer. 2019;
[Pubmed]  [Google Scholar] [DOI]
5 Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology
Darren Ming-Chun Poon,Chi-Kwok Chan,Tim-Wai Chan,Foon-Yiu Cheung,Philip Wai-Kay Kwong,Eric Ka-Chai Lee,Angus Kwong-Chuen Leung,Simon Yiu-Lam Leung,Wai-Kit Ma,Hing-Shing So,Po-Chor Tam,Lap-Yin Ho
BJU International. 2018;
[Pubmed]  [Google Scholar] [DOI]
6 TGF-ß receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer
Channing Paller,Hong Pu,Diane E. Begemann,Cameron A. Wade,Patrick J. Hensley,Natasha Kyprianou
The Prostate. 2018;
[Pubmed]  [Google Scholar] [DOI]
7 Prostate Tumor Neuroendocrine Differentiation via EMT: The Road Less Traveled
Haley Dicken,Patrick J. Hensley,Natasha Kypriaou
Asian Journal of Urology. 2018;
[Pubmed]  [Google Scholar] [DOI]
8 CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells
Ariunbold Natsagdorj,Kouji Izumi,Kaoru Hiratsuka,Kazuaki Machioka,Hiroaki Iwamoto,Renato Naito,Tomoyuki Makino,Suguru Kadomoto,Kazuyoshi Shigehara,Yoshifumi Kadono,Wen-Jye Lin,Aerken Maolake,Atsushi Mizokami
Cancer Science. 2018;
[Pubmed]  [Google Scholar] [DOI]
9 Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis
Mike Fang,Mary Nakazawa,Emmanuel S. Antonarakis,Chun Li
Prostate Cancer. 2017; 2017: 1
[Pubmed]  [Google Scholar] [DOI]
10 Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial
Kouji Izumi,Atsushi Mizokami,Mikio Namiki,Shogo Inoue,Nobumichi Tanaka,Yuko Yoshio,Kei Ishibashi,Manabu Kamiyama,Noriyasu Kawai,Hideki Enokida,Takashi Shima,Shizuko Takahara
BMC Cancer. 2017; 17(1)
[Pubmed]  [Google Scholar] [DOI]
11 Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer
Bryan Hoang,Mark J. Ernsting,Wei-Hsin Sophia Tang,Joseph Bteich,Elijus Undzys,Taira Kiyota,Shyh-Dar Li
Cancer Letters. 2017; 410: 169
[Pubmed]  [Google Scholar] [DOI]
12 The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance
Lorenzo Bascetta,Arianna Oliviero,Romina D’Aurizio,Monica Evangelista,Alberto Mercatanti,Marco Pellegrini,Francesca Marrocolo,Sergio Bracarda,Milena Rizzo
International Journal of Molecular Sciences. 2017; 18(7): 1512
[Pubmed]  [Google Scholar] [DOI]
13 Mechanisms of Therapeutic Resistance in Prostate Cancer
Mary Nakazawa,Channing Paller,Natasha Kyprianou
Current Oncology Reports. 2017; 19(2)
[Pubmed]  [Google Scholar] [DOI]
14 Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide
Dominic Pilon,Ajay S. Behl,Lorie A. Ellis,Bruno Emond,Patrick Lefebvre,Nancy A. Dawson
Journal of Managed Care & Specialty Pharmacy. 2016; : 1
[Pubmed]  [Google Scholar] [DOI]
15 Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer
Konstantina Skaltsa,Cristina Ivanescu,Shevani Naidoo,De Phung,Stefan Holmstrom,Nicholas R. Latimer
Targeted Oncology. 2016;
[Pubmed]  [Google Scholar] [DOI]
16 Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147–53
Kevin Lu
European Urology. 2015; 68(6): e129
[Pubmed]  [Google Scholar] [DOI]
17 Aminomethylphosphonic Acid and Methoxyacetic Acid Induce Apoptosis in Prostate Cancer Cells
Keshab Parajuli,Qiuyang Zhang,Sen Liu,Zongbing You
International Journal of Molecular Sciences. 2015; 16(5): 11750
[Pubmed]  [Google Scholar] [DOI]
18 One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer
Hossein Jadvar,Sudha Challa,David I. Quinn,Peter S. Conti
Cancer Biotherapy and Radiopharmaceuticals. 2015; 30(5): 195
[Pubmed]  [Google Scholar] [DOI]
19 Navigating Treatment of Metastatic Castration- Resistant Prostate Cancer: Nursing Perspectives
Frank dela Rama,Caroline Pratz
Clinical Journal of Oncology Nursing. 2015; 19(6): 723
[Pubmed]  [Google Scholar] [DOI]
20 Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer
Avishay Sella,Tal Sella,Avivit Peer,Raanan Berger,Stephen Jay Frank,Eli Gez,David Sharide,Henry Hayat,Ekaterina Hanovich,Svetlana Kovel,Eli Rosenbaum,Victoria Neiman,Daniel Keizman
Clinical Genitourinary Cancer. 2014;
[Pubmed]  [Google Scholar] [DOI]

 

Read this article